Summary:
- This article, published in *Nature Reviews Clinical Oncology*, provides a comprehensive analysis of the current landscape and future directions for antibody–drug conjugates (ADCs) in the treatment of solid tumors.
- It examines the mechanisms of action, clinical efficacy, and resistance patterns of next-generation ADCs, highlighting their evolving role as a cornerstone of precision oncology.